Longitudinal dynamics of symptom networks in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a prospective cohort study - Report - MDSpire
Advertisement
Longitudinal dynamics of symptom networks in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a prospective cohort study
Clinical Report: Temporal Changes in Symptom Networks in DTC Patients
Overview
This study investigates the dynamic changes in symptom networks among differentiated thyroid cancer patients undergoing radioactive iodine therapy. Key findings reveal that psychological distress remains central throughout treatment, while throat/mouth symptoms serve as critical bridges between physical and psychological symptoms.
Background
Differentiated thyroid cancer (DTC) patients often experience significant physical and psychological symptoms during radioactive iodine (RAI) therapy, impacting their quality of life. Understanding the interplay of these symptoms is crucial for improving patient care and developing targeted interventions. This study employs network analysis to elucidate the relationships among symptoms over time, highlighting the need for comprehensive symptom management strategies.
Data Highlights
Timepoint
Strength Centrality (Psychological Distress)
Bridge Strength (Throat/Mouth Symptoms)
Predictability (Throat/Mouth Symptoms)
T0
1.405
0.107
0.064
T1
1.473
1.017
0.782
T2
1.640
1.016
0.782
Key Findings
Network structure showed significant changes across treatment phases (T0-T1: M = 0.306, P = 0.001; T0-T2: M = 0.347, P = 0.001).
Psychological distress had the highest strength centrality at all timepoints, indicating its persistent impact.
Throat/mouth symptoms acted as a critical bridge between physical and psychological symptoms, especially post-treatment.
Predictability of treatment-related physical symptoms increased significantly from T0 to T1-T2.
RAI therapy led to substantial network reorganization rather than mere symptom accumulation.
Clinical Implications
Healthcare providers should prioritize monitoring psychological distress in DTC patients undergoing RAI therapy, as it remains a central symptom throughout treatment. Additionally, addressing throat/mouth symptoms may improve overall symptom management and patient quality of life during the treatment-to-surveillance transition.
Conclusion
The findings underscore the importance of understanding symptom networks in DTC patients to enhance management strategies. Targeting bridge symptoms could be pivotal in improving patient outcomes during and after RAI therapy.
